Alvotech (ALVO) Price & Analysis

Compare

232 Followers

ALVO Stock Chart & Stats

$8.59

$0.06(0.46%)

At close: Jan 08 4:00 PM EST

$8.59

$0.06(0.46%)

Day’s Range― - ―

52-Week Range$4.70 - $13.70

Previous CloseN/A

Volume41.59K

Average Volume (3M)642.54K

Market Cap

$1.66B

Enterprise Value$3.71B

Total Cash (Recent Filing)$42.85M

Total Debt (Recent Filing)$1.28B

Price to Earnings (P/E)23.8

Beta0.92

Next Earnings

Apr 01, 2026

EPS Estimate

-0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding301,805,660

10 Day Avg. Volume1,202,235

30 Day Avg. Volume642,537

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)-8.59

Price to Sales (P/S)7.24

P/FCF Ratio-12.06

Enterprise Value/Market Cap2.24

Enterprise Value/Revenue6.50

Enterprise Value/Gross Profit11.72

Enterprise Value/Ebitda51.07

Forecast

1Y Price Target

$10.67

Price Target Upside24.21% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Business ModelConsistent execution has validated the business model.

Global PartnershipsGlobal partnerships maximise the geographic reach of the portfolio, while the royalty/milestone-based business model should lead to elevated margins.

Pipeline DevelopmentsPositive developments in the pipeline with 3 new biosimilar launches by the end of 2025 and a visible pipeline in the mid and long-term.

Bears Say

Alvotech News

Alvotech initiated with an Underweight at Barclays

Barclays analyst Glen Santangelo initiated coverage of Alvotech (ALVO) with an Underweight rating and $5 price target The...

3d ago

ALVO

Alvotech price target lowered to $10 from $14 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Alvotech (ALVO) to $10 from $14 and keeps an Overweight...

9d ago

ALVO

Alvotech announces European Commission approval for AVT03

Alvotech (ALVO) announced that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva. Published...

18d ago

ALVO

Alvotech price target lowered to $10 from $13 at UBS

UBS lowered the firm’s price target on Alvotech (ALVO) to $10 from $13 and keeps a Buy rating...

24d ago

ALVO

Alvotech’s AVT03 Biosimilar Gains European Approval

The latest update is out from Alvotech ( ($ALVO) ). On November 24, 2025, Alvotech announced that its...

18d ago

ALVO

Alvotech’s Gobivaz® Receives European Approval as First Simponi® Biosimilar

The latest update is out from Alvotech ( ($ALVO) ). On November 20, 2025, Alvotech, in partnership with...

22d ago

ALVO

Alvotech Reports Strong Revenue Growth and New Biosimilar Approvals

An update from Alvotech ( ($ALVO) ) is now available. On November 12, 2025, Alvotech announced its financial...

25d ago

ALVO

Alvotech Reports Strong Turnaround in Financial Performance

Alvotech ( ($ALVO) ) has released its Q3 earnings. Here is a breakdown of the information Alvotech presented...

28d ago

ALVO

Alvotech’s Earnings Call: Growth Amid Challenges

Alvotech (($ALVO)) has held its Q3 earnings call. Read on for the main highlights of the call. During...

28d ago

ALVO

UK High Court Supports Alvotech’s Biosimilar Launch Plans

Alvotech ( ($ALVO) ) has shared an announcement. On November 10, 2025, Alvotech announced that the UK High...

29d ago

ALVO

ALVO Upcoming Earnings Report: What to Expect?

Alvotech (ALVO) is scheduled to report 3rd quarter earnings on 11/12/2025, after the market closes. Regarding Q3 estimates,...

1M ago

ALVO

Alvotech’s Gobivaz Biosimilar Gains UK Approval

An announcement from Alvotech ( ($ALVO) ) is now available. On November 6, 2025, Alvotech announced that the...

1M ago

ALVO

Alvotech price target lowered to $10 from $28 at Northland

Northland lowered the firm’s price target on Alvotech (ALVO) to $10 from $28 and keeps an Outperform rating...

1M ago

ALVO

Deutsche downgrades Alvotech on AVT05 complete response letter

Deutsche Bank downgraded Alvotech (ALVO) to Hold from Buy with a price target of $8, down from $14,...

1M ago

ALVO

ALVO FAQ

What was Alvotech’s price range in the past 12 months?

Alvotech lowest stock price was $4.70 and its highest was $13.70 in the past 12 months.

What is Alvotech’s market cap?

Alvotech’s market cap is $1.66B.

When is Alvotech’s upcoming earnings report date?

Alvotech’s upcoming earnings report date is Apr 01, 2026 which is in 110 days.

How were Alvotech’s earnings last quarter?

Alvotech released its earnings results on Nov 12, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.027 by -$0.073.

Is Alvotech overvalued?

According to Wall Street analysts Alvotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alvotech pay dividends?

Alvotech does not currently pay dividends.

What is Alvotech’s EPS estimate?

Alvotech’s EPS estimate is -0.08.

How many shares outstanding does Alvotech have?

Alvotech has 301,805,660 shares outstanding.

What happened to Alvotech’s price movement after its last earnings report?

Alvotech reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.027. Following the earnings report the stock price went down -1.429%.

Which hedge fund is a major shareholder of Alvotech?

Currently, no hedge funds are holding shares in ALVO

Alvotech Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

14.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alvotech

Alvotech (ALVO) is a biotechnology company focused on developing and manufacturing biosimilars, which are biologic medical products highly similar to already approved reference products. The company operates primarily in the pharmaceutical sector, specializing in monoclonal antibodies and other biologics. Alvotech aims to provide affordable access to high-quality medicines for patients worldwide by leveraging its proprietary technology platform and expertise in large-scale bioprocessing.

Alvotech (ALVO) Earnings & Revenues

Historic Earnings Reports

ALVO Company Deck

ALVO Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a company with strong growth and strategic investments, but it is facing significant regulatory and operational challenges that have impacted its short-term financial outlook.View all ALVO earnings summaries

ALVO Stock 12 Month Forecast

Average Price Target

$10.67

▲(24.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","6":"$6","9":"$9","12":"$12","15":"$15"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6,9,12,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.84,5.544615384615384,6.249230769230769,6.953846153846154,7.658461538461538,8.363076923076923,9.067692307692308,9.772307692307692,10.476923076923077,11.181538461538462,11.886153846153846,12.590769230769231,13.295384615384616,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.84,5.288461538461538,5.736923076923077,6.185384615384615,6.633846153846154,7.082307692307692,7.530769230769231,7.979230769230769,8.427692307692308,8.876153846153846,9.324615384615385,9.773076923076923,10.221538461538461,{"y":10.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.84,5.083076923076923,5.326153846153846,5.569230769230769,5.812307692307693,6.055384615384615,6.298461538461538,6.541538461538462,6.7846153846153845,7.027692307692307,7.270769230769231,7.513846153846154,7.756923076923076,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.66,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.22,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.79,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >